TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Study Comparing Foster Efficacy Maintenance and Reliever Versus Foster Maintenance + Salbutamol Reliever in Asthmatics

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Written signed and dated informed consent obtained.~* Male or female patients aged ≥ 18 years.~* A positive reversibility test~* Patients who experienced at least one severe exacerbation in the 12 months before entry (but not in the last month)~* Using inhaled corticosteroids (ICS) in monotherapy or using ICS in a fixed or free combination with long acting beta2 agonists (LABA) at a constant dose for two months before screening visit~* Not fully controlled asthmatics (which means partly controlled or/and uncontrolled patients according to GINA guidelines 2007) in the last month before screening visit~* Forced expiratory volume in the first second (FEV1) ≥ 60% of predicted for the patient normal value.~* Non smokers or ex-smokers~Exclusion Criteria:~* Pregnant or nursing (lactating) women. Women of child-bearing potential UNLESS they meet the following definition of post-menopausal: 12 months of natural (spontaneous) amenorrhea or 6 months of spontaneous amenorrhea with serum FSH levels \>40 mIU/mL or are using one or more of acceptable methods of contraception~* Body Mass Index (BMI) \> 34 kg/m2.~* Patient with lower respiratory tract infections affecting the patient's asthma within 30 days of the screening visit.~* Use of systemic steroids in the last month.~* Patients with other lung diseases such as COPD, cystic fibrosis, interstitial lung diseases or any other clinically or functionally significant lung disorder.~* Patients who have an uncontrolled respiratory, haematological, immunologic, renal, neurologic, hepatic, endocrinal or other disease.~* Clinically relevant laboratory abnormalities~* Patients who have an abnormal QTcF interval value~* Intolerance or contra-indication to treatment with beta2-agonists and/or ICS or allergy to any component of the study treatments.~* Patients treated with slow-release corticosteroids in the 3 months prior to screening visit.~* Patients being treated with anti-IgE antibodies.~* Patients treated with LABA or ICS/LABA fixed combination in the 24h before screening visit~* Severe asthma exacerbation in the last month before screening visit

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Beclometasone/formoterol (100/6 µg) (Type: EXPERIMENTAL): Foster : fixed combination of BDP extrafine 100 µg plus formoterol fumarate 6 µg administered via a pMDI standard actuator
- salbutamol (Type: ACTIVE_COMPARATOR): Ventolin : salbutamol sulphate 100 µg per metered dose

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy of AIN457 in Noninfectious Uveitis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 8.0

Eligibility Criteria:
Inclusion criteria:~* Active uveitis (i.e., uveitis that is not in remission).~* Intermediate uveitis, posterior uveitis, or panuveitis must be sufficiently severe that systemic immunosuppression is indicated.~Exclusion criteria:~* Active infection.~* Weight must not be greater that 120kg.~Other protocol-defined inclusion/exclusion criteria may apply

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Cohort 1 (Type: EXPERIMENTAL): Participants were administered with AIN457 (Sp2/0derived) 10 milligrams per kilogram (mg/kg) intravenous (i.v.) dose on Day 1 and Day 22.
- Cohort 2 (Type: EXPERIMENTAL): Participants were administered with AIN457 (Sp2/0 or Chinese hamster ovary cell (CHO) derived) 10 mg/kg, (CHO derived) 3 mg/kg or (CHO derived) 1 mg/kg i.v. dose on Day 1 and if needed a second dose of AIN457 10 mg/kg i.v. dose either on Day 15 or Day 22. 3 participants from cohort 1 rolled on into this cohort.
- Cohort 3 (Type: EXPERIMENTAL): Participants were administered with AIN457 10 mg/kg i.v. dose on Day 1 and Day 22.
- Cohort 4 (Type: EXPERIMENTAL): Extension period: Participants were administered with AIN457 10 mg/kg, i.v. (with or without a short course of corticosteroids) once a flare had occurred, or periodically at a frequency of not more than once per month at the discretion of the investigator.
- Cohort 5 (Type: EXPERIMENTAL): Participants were administered with AIN457 30 mg/kg single i.v. dose. A second dose was given when all 4 participants completed at least 29 days, and the 30 mg/kg dose was well tolerated by all.
- Cohort 6 Arm 1 (Type: EXPERIMENTAL): Participants were administered with AIN457 300 mg subcutaneously (s.c.) and saline i.v. infusion every two weeks (Days 1, 15, 29, and 43).
- Cohort 6 Arm 2 (Type: EXPERIMENTAL): Participants were administered with AIN457 10 mg/kg i.v. and s.c. saline injections every two weeks (Days 1, 15, 29, and 43).
- Cohort 6 Arm 3 (Type: EXPERIMENTAL): Participants were administered with AIN457 30 mg/kg i.v. and s.c. saline injections every 4 weeks (Days 1 and 29) and saline i.v. infusions and saline s.c. injections on Days 15 and 43 to maintain masking of treatment groups.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of PRO-148 Versus Systane®, in Patients With Mild to Moderate Dry Eye

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Mild to moderate dry eye patients based on the Report of International Dry Eye Workshop (DEWS)~* OSDI score between 12 and 45~* Provided informed consent~Exclusion Criteria:~* Patients with one blind eye~* Visual acuity of 20/100 or worst in any eye~* Patients with any active ocular disease that would interfere with study interpretation~* Patients in treatment with any medication that could interfere with the study, contraindication of any medication used in the protocol~* Patients with history of hypersensitivity or contraindication for any drug used in the study~* Contact lens users~* Pregnant patients, at risk of pregnancy or breastfeeding~* Patients without birth control treatment~* Patients who had participated in any clinical trial in the last 90 days~* Legal or mentally disabled patients who could not give informed consent~* Patients who do not provide informed consent

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- PRO-148 (Type: EXPERIMENTAL): PRO-148 containing: xanthan gum and sulphate chondroitin, ophthalmic solution~doses: 1 drop in each eye, quarter in day
- Systane® (Type: ACTIVE_COMPARATOR): Systane containing: polyethylene glycol 400 0.4%, propylene glycol 0.3% and hydroxypropyl guar~doses: 1 drop in each eye, quarter in day

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Gemcitabine and Liposomal Doxorubicin in Treating Women With Metastatic Breast Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: None

Eligibility Criteria:
DISEASE CHARACTERISTICS: Histologically confirmed metastatic breast cancer Bidimensionally measurable disease No uncontrolled brain metastases or leptomeningeal disease Brain metastases treated with surgery and/or radiotherapy allowed if neurologic status is stable two weeks after last dose of dexamethasone Hormone receptor status: Not specified~PATIENT CHARACTERISTICS: Age: 18 and over Sex: Female Menopausal status: Not specified Performance status: Zubrod 0-2 Life expectancy: At least 3 months Hematopoietic: Platelet count at least 100,000/mm3 Hemoglobin at least 8 g/dL Absolute neutrophil count at least 1,500/mm3 Hepatic: Bilirubin no greater than 1.2 mg/dL SGPT less than 1.5 times upper limit of normal Renal: Creatinine no greater than 2.0 mg/dL Cardiovascular: LVEF at least 50% by MUGA No cardiac disease or congestive heart failure Other: Not pregnant or nursing Negative pregnancy test Fertile patients must use effective contraception No other concurrent serious illness, psychiatric disorder, or active infection No other prior or concurrent malignancy within the past 5 years except nonmelanoma skin cancer or carcinoma in situ of the cervix~PRIOR CONCURRENT THERAPY: Biologic therapy: No prior high-dose chemotherapy followed by bone marrow transplantation Chemotherapy: See Biologic Therapy At least 3 weeks since prior chemotherapy and recovered No prior doxorubicin HCl liposome or gemcitabine Prior neoadjuvant chemotherapy allowed At least 12 months since prior adjuvant anthracycline-based therapy and no evidence of anthracycline resistance (i.e., developed progressive disease while receiving adjuvant therapy or within 6 months of completing adjuvant therapy) Prior mitoxantrone allowed if total dose was no greater than 105 mg/m2 IV bolus or 140 mg/m2 IV continuous infusion Prior doxorubicin allowed if total dose was no greater than 300 mg/m2 IV bolus or 400 mg/m2 IV continuous infusion No prior chemotherapy for metastatic disease Endocrine therapy: Prior adjuvant and/or palliative hormonal therapy allowed Radiotherapy: See Disease Characteristics At least 3 weeks since prior radiotherapy and recovered Surgery: See Disease Characteristics Prior surgery allowed Other: At least 3 weeks since prior investigational study Concurrent pamidronate allowed if bone not the only site of disease

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Influence of Intensive Lipid Lowering Treatment Compared to Moderate Lipid Lowering Treatment on Plaque Composition in Patients With ST-Segment Elevation Myocardial Infarction (MI)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* ST segment elevation acute myocardial infarction~* 20% \< angiographic diameter stenosis \< 50% on a not previously revascularized native coronary artery~* Statin naïve~Exclusion Criteria:~* Pharmacologic lipid lowering treatment before index hospitalization~* Atrial fibrillation, not well rate-controlled~* Ventricle frequency variation with more than a factor 2 over 1 minute~* Unconscious patients~* Total cholesterol \> 7.0 mmol/l~* History of statin induced myopathy, or serious hypersensitivity reaction to other HMG-CoA reductase inhibitors (statins) including rosuvastatin~* Pregnant women, women who are breast feeding, and women of childbearing potential who are not using chemical or mechanical contraception or have a positive serum pregnancy test (a serum-human chorionic gonadotrophin \[Beta-HCG\] analysis)~* History of malignancy (unless a documented disease free period exceeding 5-years is present) with the exception of basal cell or squamous cell carcinoma of the skin, or in the case of a study designed to investigate antineoplastic properties of rosuvastatin. Women with a history of cervical dysplasia would be permitted to enter the study provided they had 3 consecutive clear Papanicolaou (Pap) smears~* Uncontrolled hypothyroidism (TSH \> 1.5xULN)~* Abnormal LFT's~* History of alcohol or drug abuse within the last 5 years (this may affect compliance)~* Current active liver disease (ALT/SGPT \>2xULN or severe hepatic impairment (to protect patient safety as directed on the labels of currently approved statins)~* Unexplained creatine kinase (CK \> 3xULN) (To protect patient safety) (will be increased at baseline because of acute ST segment elevation myocardial infarction a few days before enrolment)~* Serum creatinine \>176mmol/L (2.0mg/dL) (unless the protocol specifically aims to investigate a chronic renal disease population)~* Participation in another investigational drug study less than 4 weeks before enrolment in the study, or according to subjects local ethics committee requirements where a larger period is stipulated (to avoid potential misinterpretation of overlapping adverse events)~* Treatments with cyclosporine~* Treatment with gemfibrozil

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 81 Years
- Healthy Volunteers: f

Study Arms:
- Rosuvastatin 5mg (Type: ACTIVE_COMPARATOR): Rosuvastatin 5mg/day for one year
- Rosuvaststin 40mg (Type: ACTIVE_COMPARATOR): Rosuvastatin 40mg/day

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study to Learn About the Study Medicine (Avelumab) in Japanese Patients With Urothelial Carcinoma That Has Spread

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: RETROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~1. Diagnosed with locally advanced or metastatic UC before receiving Avelumab 1L maintenance therapy.~2. Started treatment with avelumab for locally advanced or metastatic UC from 24 Feb 2021 (regulatory approval date) to 30 Nov 2021.~3. Evidence of a personally signed and dated informed consent document indicating that the patient (or a legally acceptable representative) has been informed of all pertinent aspects of the study.~(1) Written consent is not required for patients who were transferred to a hospital, and registration with verbal consent is acceptable.~(2) Opt-out enrollment is allowed for patients who have already died. 4)Deceased patients are also required to meet the inclusion criteria 1)-2).~Exclusion Criteria:~There are no exclusion criteria for this study.

- Gender: ALL
- Minimum Age: 0 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Japanese Patients With Locally Advanced or Metastatic Urothelial Carcinoma (Type: None): Japanese Patients With Locally Advanced or Metastatic Urothelial Carcinoma who were treated with avelumab as first-line maintenance therapy

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: MK3207 for Treatment of Acute Migraines (3207-005)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 7.0

Eligibility Criteria:
Inclusion Criteria:~* Men and Women from 18 to 65 years of age~* 1+ year history of migraine that typically last from 4 to 72 hours if untreated~* Had from 2 to 8 moderate or severe migraine attacks per month in the last 2 months~* Not pregnant or planning to become pregnant in next 6 months~Exclusion Criteria:~* Pregnant or breast-feeding, or planning to become pregnant in next 6 months~* Cannot distinguish migraine attacks from tension type headaches~* Migraines are mild or resolve without medication in less than 2 hours~* More than 15 headache-days per month or have taken medication on more than 10 days per month in the last 3 months~* Basilar type or hemiplegic migraine headaches~* More than 50 years old when migraines began~* History of cardiovascular disorder within last 6 months

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): MK3207- 2.5 mg
- 2 (Type: EXPERIMENTAL): MK3207- 5 mg
- 3 (Type: EXPERIMENTAL): MK3207- 10 mg
- 4 (Type: EXPERIMENTAL): MK3207- 20 mg
- 5 (Type: EXPERIMENTAL): MK3207- 50 mg
- 6 (Type: EXPERIMENTAL): MK3207- 100 mg
- 7 (Type: PLACEBO_COMPARATOR): Placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: The Effect on Blood Cells, Known as Platelets, Using Prasugrel vs Clopidogrel in Patients With the Heart Problem Acute Coronary Syndrome (ACS)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Present with acute coronary syndrome (ACS) and have planned treatment with a one-time 900-mg loading dose of commercially available clopidogrel (administered as a single or cumulative dose).~* Are between the ages of 18 and 85 years.~* Willing and able to sign informed consent.~Exclusion Criteria:~* Have overt ST-segment elevation myocardial infarction (STEMI).~* Have cardiogenic shock.~* Have refractory ventricular arrhythmias.~* Have New York Heart Association (NYHA) Class IV congestive heart failure.~* Have severe and uncontrolled hypertension.~* Have active internal bleeding or history of bleeding diathesis.~* Have an increased risk of bleeding.~* Have history of cerebrovascular accidents.~* Have certain abnormal blood level values.~* Are currently receiving chemotherapy or radiation therapy.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 85 Years
- Healthy Volunteers: f

Study Arms:
- Prasugrel (Type: EXPERIMENTAL): Open label lead-in one time dose of Clopidogrel 900 mg oral tablets (a single or cumulative dose) and 250 mg to 500 mg aspirin loading dose (LD), either orally or intravenously. Patients are then assigned to maintenance dose (MD) prasugrel 10 mg and two placebo tablets, matched to clopidogrel, and 100 mg aspirin, all taken orally once a day for 14 days. Patients cross-over to MD of clopidogrel two 75 mg tablets and one placebo matched to prasugrel and 100 mg aspirin, all taken orally once a day for the next 14 days.
- Clopidogrel (Type: ACTIVE_COMPARATOR): Open label lead-in one time dose of Clopidogrel 900 mg oral tablets (a single or cumulative dose) and 250 mg to 500 mg aspirin loading dose (LD), either orally or intravenously. Patients are then assigned to maintenance dose (MD) Clopidogrel two 75 mg and one placebo tablet, matched to prasugrel, and 100 mg aspirin, all taken orally once a day for 14 days. Patients cross-over to MD of prasugrel one 10 mg tablet and two placebo tablets matched to clopidogrel and 100 mg aspirin, all taken orally once a day for the next 14 days.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Interventions to Improve Specialty Medication Adherence

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* The same medication (at the Generic Product Identifier level 12) filled ≥4 times in the 12 months before date of import into the study database~* Prescription generated from one of the following Vanderbilt outpatient specialty clinics: Pediatric Rheumatology, Pediatric Gastroenterology/Inflammatory Bowel Disease, adult Vanderbilt Rheumatology clinics, Dermatology, Hematology, Adult Endocrinology, Neurology, Asthma Sinus \& Allergy, Idiopathic Pulmonary Fibrosis, Pulmonary Arterial Hypertension, Cystic Fibrosis, Multiple Sclerosis, Neurology, or a Lipid clinic~* Proportion of Days Covered (PDC) \< 90% over the previous 4 months and 12 months~Exclusion Criteria:~* Prescription issued by a non-VUMC provider~* Planned treatment discontinuation in the subsequent eight months~* More than one unique specialty medication from the same clinic in the previous four months~* Patients with \> 30 gap days in the previous four months and whose last fill was \> 30 days from importing into the study database.~* Any reason for misidentified nonadherence in the previous four months~* Deceased patients~* Incarcerated patients

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Pharmacist-Driven Intervention (Type: EXPERIMENTAL): The study group will receive a patient-tailored, pharmacist-driven intervention(s) to overcome patient-specific barriers to adherence. Each patient in the study group will be intervened upon using a protocol that is based on their reason for non-adherence.
- Standard of Care (Type: NO_INTERVENTION): The usual care group will receive the standard of care provided to all patients that utilize Vanderbilt Specialty Pharmacy.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Aflibercept in Patients With Pigment Epithelial Detachments (PED)

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: OTHER
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Patients with vascular PED due to AMD~* Male or female patients with the age \> 50 years~* Angiographic and via OCT ensured PED ≥ 200 µm in the eye for treatment~* Written informed consent~* Best corrected visual acuity (ETDRS-Visus): 24 - 73 letters within~Exclusion Criteria:~* Patients that do not fulfill the a. m. inclusion criteria~* Patients which have been treated with steroids or with verteporfin via photodynamic therapy or focal lasercoagulation treatment until 3 months before,~* Anti VEGF therapy until 1 month before screening~* Patients with other retinal vascular diseases including diabetic rethinopathia or retinal vein occlusion~* Other ocular operative procedurs 3 months before Screening~* Anamnesis of non controlled glaucoma~* Active or intraocular Inflammation or Inflammation of ocular adnexa~* Subfoveal fibrosis within study eye~* Larger surgical interventions 1 month before Screening~* Anamnesis of serious cardiovascular diseases or stroke 6 months before srceening~* Allergy of components of the study medication~* Patients which might be not compliant~* Patients participating at another clinical trial at the same time~* Pregnancy, breastfeeding, women in child-bearing years without using a safe contraception method~* Chronical alcohol- or drug abuse within the last year~* lack of capacity and/or knowledge of German language~* Neurologic disease i. e. multiple sclerosis

- Gender: ALL
- Minimum Age: 50 Years
- Maximum Age: None
- Healthy Volunteers: None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete